<DOC>
	<DOCNO>NCT02284893</DOCNO>
	<brief_summary>A combination saxagliptin dapagliflozin add concurrently metformin combination diet exercise superior sitagliptin add metformin combination diet exercise reduce mean HbA1c treatment period 26 week .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Saxagliptin Co-administered With Dapagliflozin Combination With Metformin Compared Sitagliptin Combination With Metformin Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control Metformin Therapy Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patients Type 2 diabetes mellitus ( T2DM ) inadequate glycemic control , define central laboratory glycosylated hemoglobin ( HbA1c ) ≥8.0 % ≤ 10.5 % obtain screen visit Subjects take daily dose metformin ≥ 1500 mg least 8 week prior enrollment visit intake antihyperglycemic therapy 14 day ( consecutive ) 12 week prior screen BMI &gt; 20.0 kg/m2 enrollment visit Males Females , age ≥18 year old time screen visit Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start study drug Women must breastfeed Clinically diagnosed Type I diabetes , know diagnosis Maturity Onset Diabetes Young ( MODY ) , secondary diabetes mellitus diabetes insipidus History diabetic ketoacidosis Any follow cardiovascular ( CV ) /Vascular Diseases within 3 month enrollment visit Myocardial infarction Cardiac surgery revascularization ( coronary artery bypass surgery Coronary Artery Bypass Graft [ ( CABG ) ] /percutaneous transluminal coronary angioplasty percutaneous transluminal coronary angioplasty [ ( PTCA ) ] ) Unstable angina Unstable congestive heart failure ( CHF ) Transient ischemic attack ( TIA ) significant cerebrovascular disease Unstable previously undiagnosed arrhythmia Congestive heart failure , define New York Heart Association ( NYHA ) Class III IV , unstable acute congestive heart failure and/or know leave ventricular ejection fraction ≤ 40 % Renal Disease Hepatic Diseases Hematological Oncological Disease/Conditions Hemoglobin ≤ 11.0 g/dL ( 110 g/L ) men ; hemoglobin ≤ 10.0 g/dL ( 100 g/L ) woman Abnormal Free T4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>